Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Herestraat, Leuven, Belgium.
Curr Opin Obstet Gynecol. 2011 Feb;23(1):3-7. doi: 10.1097/gco.0b013e32834156e5.
For more than a decade, proteomic techniques have been used to unravel the nature and function of human proteins. In 2002 it came to the attention of clinicians that this technique could be used to discover new biomarkers. However, the first reports were hampered by technical and methodological flaws. Since these first reports, proteomics has matured and the technical abilities have grown enormously. An in-depth analysis of fluid or tissue specimens is now possible. We reviewed recent literature to see whether proteomics has changed our clinical practice in the diagnosis and treatment of gynecological cancers.
In ovarian cancer a great effort has been put into discovering new diagnostic and screening markers. Several proteins have been put forward as possible candidates to fulfill this task. However, none of the proteins turned out to be better than CA125 alone. In endometrial cancer many of the presumed tumor markers are not specific for endometrial cancer but are more tumor markers for cancer in general. The same problem was noticed in cervical cancer. Papers are now focusing more on therapy response and carcinogenesis.
To date, proteomic studies have not been able to change our clinical practice in gynecological oncology.
十多年来，蛋白质组学技术被用于揭示人类蛋白质的性质和功能。2002 年，临床医生开始注意到，这项技术可以用于发现新的生物标志物。然而，最初的报告受到技术和方法缺陷的阻碍。自最初的报告以来，蛋白质组学已经成熟，技术能力有了巨大的发展。现在可以对液体或组织标本进行深入分析。我们回顾了最近的文献，以了解蛋白质组学是否改变了我们在妇科癌症的诊断和治疗中的临床实践。
在卵巢癌中，人们努力发现新的诊断和筛查标志物。已经提出了几种蛋白质作为可能完成这项任务的候选者。然而，没有一种蛋白质比单独的 CA125 更好。在子宫内膜癌中，许多假定的肿瘤标志物不是子宫内膜癌特有的，而是更常见的癌症的肿瘤标志物。在宫颈癌中也注意到了同样的问题。现在的论文更侧重于治疗反应和癌变。
迄今为止，蛋白质组学研究还不能改变我们在妇科肿瘤学中的临床实践。
